Cancer Frequencies: Finally a Clinical Trial

We've known for decades that frequencies are an excellent approach to treating cancer with dramatically less side effects than chemotherapy and radiation. It is nice to finally see a group do a successful clinical trial on this.

This team did not even use frequencies in the range known to kill cancer cells and were successful. Image what they could if they utilized the expertise in the worldwide community working with this technology!

An important finding (pointed out for many years on this site) is that frequencies are specific to specific cells and cell types. This makes it challenging for the average university research groups. As Rife has shown us, getting the exact frequencies requires painstaking work for many years with highly refined tools not generally available. 

Also well known, and can be inferred by the data in this study, is that it is difficult to eliminate cancer completely for terminal cases, but possible to signficantly increase the life span and quality of life compared to conventional treatment. 
------


Amplitude-modulated electromagnetic fields for the treatment of cancer: Discovery of tumor-specific frequencies and assessment of a novel therapeutic approach
Alexandre Barbault, Frederico P Costa , Brad Bottger , Reginald F Munden , Fin Bomholt , Niels Kuster  and Boris Pasche
Cabinet Médical, Avenue de la Gare 6, Lausanne, Switzerland
Rue de Verdun 20, Colmar, FranceSirio-Libanes Hospital, Oncology Center, São Paulo, Brazil
Radiology Associates, Danbury Hospital, Danbury, CT, USA
5Department of Radiology, The University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL, USA
SPEAG AG, Zurich, Switzerland
IT'IS, Swiss Federal Institute of Technology, Zurich, Switzerland
Division of Hematology/Oncology, Department of Medicine, The University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL, USA

Journal of Experimental & Clinical Cancer Research 2009, 28:51doi:10.1186/1756-9966-28-51

The electronic version of this article is the complete one and can be found online at: http://www.jeccr.com/content/28/1/51

Received:    8 January 2009
Accepted:    14 April 2009
Published:    14 April 2009
© 2009 Barbault et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose
Because in vitro studies suggest that low levels of electromagnetic fields may modify cancer cell growth, we hypothesized that systemic delivery of a combination of tumor-specific frequencies may have a therapeutic effect. We undertook this study to identify tumor-specific frequencies and test the feasibility of administering such frequencies to patients with advanced cancer.

Patients and methods
We examined patients with various types of cancer using a noninvasive biofeedback method to identify tumor-specific frequencies. We offered compassionate treatment to some patients with advanced cancer and limited therapeutic options.


Results
We examined a total of 163 patients with a diagnosis of cancer and identified a total of 1524 frequencies ranging from 0.1 Hz to 114 kHz. Most frequencies (57â€"92%) were specific for a single tumor type. Compassionate treatment with tumor-specific frequencies was offered to 28 patients. Three patients experienced grade 1 fatigue during or immediately after treatment. There were no NCI grade 2, 3 or 4 toxicities. Thirteen patients were evaluable for response. One patient with hormone-refractory breast cancer metastatic to the adrenal gland and bones had a complete response lasting 11 months. One patient with hormone-refractory breast cancer metastatic to liver and bones had a partial response lasting 13.5 months. Four patients had stable disease lasting for +34.1 months (thyroid cancer metastatic to lung), 5.1 months (non-small cell lung cancer), 4.1 months (pancreatic cancer metastatic to liver) and 4.0 months (leiomyosarcoma metastatic to liver).

Conclusion
Cancer-related frequencies appear to be tumor-specific and treatment with tumor-specific frequencies is feasible, well tolerated and may have biological efficacy in patients with advanced cancer.

Trial registration
clinicaltrials.gov identifier NCT00805337

Watch The Last Days of Lehman Brothers Online Free

A year ago I knew nothing about finance. As far as I was concerned a credit crunch was what happened when my programme's end credits were squeezed into the top right hand corner of the TV screen to make way for a "coming next".

It was a disaster movie, it was Apollo 13 with the titans of Wall Street racing the clock to save the stricken bank; it was a Greek tragedy with Lehman's chief executive brought down by his own tragic flaw; it was Twelve Angry Men with solutions sought in smoke-filled rooms

So when the global credit crunch hit the news last year and newsreaders told all about how bankers had been caught out buying and selling debt my automatic reaction was: "Oh that's a good idea, can we get someone to buy ours?"

And then Kate Harwood, Head of BBC Drama Production, sidled up to me in the middle of March and asked me to produce a 60-minute drama about the weekend Lehman Brothers went bankrupt.

'Financial idiot'

I warned her that she had picked the wrong woman and probably ought to find someone who at the very least understood the business pages of the Sunday papers, but she was firm.

If a financial idiot like me could produce a drama that explained what had happened to a financial idiot like her, we would be performing a public service.

I had only a few weeks to get very quickly up to speed.

We were working with the BBC team who were preparing a documentary series to mark the anniversary, and as soon as I read the research they had pulled together it was clear that we had all the material for a great drama.

Yes, it was about finance, but it was about so much more besides.

It was a disaster movie, it was Apollo 13 with the titans of Wall Street racing the clock to save the stricken bank; it was a Greek tragedy with Lehman's chief executive brought down by his own tragic flaw; it was Twelve Angry Men with solutions sought in smoke-filled rooms.

In mid April our scriptwriter, Bafta-nominated Craig Warner, started work and our drama began to take shape.

London's 'Fed'

James Cromwell (right) plays US Treasury Secretary Hank Paulson

We embarked on casting and met an extraordinary number of expat American actors living and working in the UK.

We were pleased to attract the talents of James Cromwell (LA Confidential, Babe, Six Feet Under, Tales of the City) to play US Treasury Secretary Hank Paulson and Corey Johnson (United 93) to play Lehman CEO Dick Fuld.

As a low budget drama for BBC Two, we were never going to be able to shoot New York in New York, so we got busy trying to find it within the M25.

We looked at office blocks for Lehman's offices, and stately homes for the boardroom at the Federal Reserve Bank of New York, (where the fate of Lehman was thrashed out a year ago).

We were startled on one location recce to find that we were being taken to the 14th-floor offices that had been used by Lehman's in London until only nine months before.

We committed to the space and found ourselves pressing Lehman's office furniture into service as… Lehman's office furniture. We had found the New York Fed just outside Croydon.

I think I understand a little more about finance now. I even read the business pages first now when the Sunday papers come.

But I wonder if it will last...

The Last Days of Lehman Brothers is broadcast on BBC Two at 2100 BST, on 9 September 2009.

Click below to watch the movie for free. subscribe for part two.
Watch The Last Days of Lehman Brothers Online Free

If you found this article interesting please subscribe for updates with any reader or your email. Also be sure to check out my soon to launch membership website TheStockman.ORG,

Bookmark & Share on ANY social site:

NYSE Arca Morning Update - 08:30:00 ET

NYSE Arca Morning Update for Thursday, Sep 10, 2009 :

STOCKS TRADING ON NYSE Arca AT A PRICE 15% OR MORE AWAY FROM
THE PREVIOUS TRADE DAY'S CONSOLIDATED CLOSE PRICE (AS OF 08:30:00 ET)

Stock Wednesday's Close Current Price Pct Change Current NYSE ARCA Vol
NCS $2.95 $3.59 21.6% 20,000

10 MOST ACTIVE STOCKS ON NYSE ARCA AS OF 08:30:00 ET

BASED ON DOLLARS TRADED: | BASED ON SHARES TRADED:
Stock $ Volume Price PctChg | Stock Share Vol Price PctChg
SPY $51,151,537 $103.63 ( 0.1%) | C 891,151 $4.61 ( 0.6%)
MON $33,268,025 $77.16 ( 7.6%) | DVAX 498,742 $3.02 69.9%
GLD $16,759,401 $96.81 ( 0.3%) | SPY 493,765 $103.63 ( 0.1%)
AEE $9,977,495 $25.61 ( 1.8%) | MON 429,225 $77.16 ( 7.6%)
AAPL $7,287,462 $171.65 0.3% | AEE 389,407 $25.61 ( 1.8%)
BHP $5,559,904 $64.44 ( 0.8%) | COR 254,900 $0.30 3.4%
QQQQ $5,284,240 $41.02 ( 0.2%) | VVUS 253,311 $12.26 4.1%
SDS $5,117,404 $42.58 0.4% | FNM 246,967 $1.68 0.6%
ASML $4,397,144 $30.52 3.9% | BAC 217,203 $17.00 ( 0.4%)
C $4,137,236 $4.61 ( 0.6%) | GLD 173,189 $96.81 ( 0.3%)

Price changes may be affected by symbol splits and dividends.

Consolidated close price is the last print (excluding prints with trade
conditions) prior to 4PM ET.

This information is also updated on our web page every morning at 8:35ET:
http://www.tradearca.com/data/volume/daily_update.asp

This material is for informational purposes only.
NYSE Euronext and its affiliates ("NYSE Arca") are not soliciting any action based upon it.
This material is not to be construed as an offer to buy or sell any security in any jurisdiction where such an offer or solicitation would be illegal.
Any opinions expressed in this material are NYSE Arca opinions only.
NYSE Arca undertakes no obligation to update any of the information contained in this material in light of new information or future events.
THIS MATERIAL IS PROVIDED BY NYSE ARCA "AS IS" AND WITHOUT WARRANTIES EXPRESS OR IMPLIED.
NYSE ARCA DISCLAIMS ALL WARRANTIES INCLUDING THE IMPLIED WARRANTIES OF MERCHANTIBILITY, TITLE, AND FITNESS FOR A PARTICULAR PURPOSE AS TO THIS MATERIAL.
IN NO EVENT SHALL NYSE ARCA BE LIABLE FOR DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER (INCLUDING BUT NOT LIMITED TO, LOST PROFITS, TRADING LOSSES AND DAMAGES THAT MAY RESULT FROM THE USE
OF THIS MATERIAL, ANY DELAY OR INTERRUPTION OF SERVICE OR OMISSIONS OR INACCURACIES IN THE MATERIAL) WITH RESPECT TO THIS MATERIAL.

Copyright [2009] by NYSE Euronext. All rights reserved. Reproduction and redistribution prohibited without prior express consent.